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Abstract: 
2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil) is commonly prescribed 
for the treatment of narcolepsy and increasing popularity and off-label use 
as a cognitive enhancer resulted in a reputation as an intelligence boosting 
‘wonder drug’. Common alternatives available from online shops and other 
retail outlets include 2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide 
(adrafinil), 2-{[bis(4-fluorophenyl)methyl]sulfinyl}acetamide (CRL-
40,940), 2-{[bis(4-fluorophenyl)methyl]sulfinyl}-N-hydroxyacetamide 
(CRL-40,941) and N-methyl-4,4-difluoro-modafinil (modafiendz), 
respectively. Gas chromatography mass spectrometry (GC-MS) is a 
common tool used in forensic and clinical analysis but there is a potential 
for inducing analysis-related ambiguities. This study reports on the thermal 
degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-
40,941 due to exposure to the heated GC injection port dissolved in a 
variety of solvents. Key degradation products common to modafinil, 
modafinic acid, adrafinil analysis included diphenylmethanol and 1,1,2,2-
tetraphenylethane (TPE), the latter of which was verified by its synthesis 
http://mc.manuscriptcentral.com/dta
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and characterization by x-ray crystallography. The investigated compounds 
were also characterized by 1H and 13C NMR. Diphenylmethane and 
thiobenzophenone were also identified in some instances. TPE formation 
was suggested to involve the generation of a benzhydrylium ion and its 
reaction with the sulfoxide oxygen of the parent compound to give an 
oxysulfonium intermediate. Correspondingly, the fluorinated TPE analog 
was formed during heat-induced degradation of modafiendz, CRL-40,940 
and CRL-40,941, respectively. When a mixture of modafinil (non-
fluorinated) and modafiendz (fluorinated) were subjected to GC analysis, 
4,4'-(2,2-diphenylethane-1,1-diyl)bis(fluorobenzene) was detected as a 
third cross reaction product in addition to the two expected TPE analogs. 
These observations served as a reminder that the seemingly 
straightforward implementation of GC-MS analysis can lead to challenges 
during routine analysis. 
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Abstract 
 
2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil) is commonly prescribed for the 
treatment of narcolepsy and increasing popularity and off-label use as a cognitive 
enhancer resulted in a reputation as an intelligence boosting ‘wonder drug’. Common 
alternatives available from online shops and other retail outlets include 2-
[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide (adrafinil), 2-{[bis(4-
fluorophenyl)methyl]sulfinyl}acetamide (CRL-40,940), 2-{[bis(4-
fluorophenyl)methyl]sulfinyl}-N-hydroxyacetamide (CRL-40,941) and N-methyl-4,4-
difluoro-modafinil (modafiendz), respectively. Gas chromatography mass 
spectrometry (GC-MS) is a common tool used in forensic and clinical analysis but 
there is a potential for inducing analysis-related ambiguities. This study reports on 
the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-
40,941 due to exposure to the heated GC injection port dissolved in a variety of 
solvents. Key degradation products common to modafinil, modafinic acid, adrafinil 
analysis included diphenylmethanol and 1,1,2,2-tetraphenylethane (TPE), the latter 
of which was verified by its synthesis and characterization by x-ray crystallography. 
The investigated compounds were also characterized by 1H and 13C NMR. 
Diphenylmethane and thiobenzophenone were also identified in some instances. 
TPE formation was suggested to involve the generation of a benzhydrylium ion and 
its reaction with the sulfoxide oxygen of the parent compound to give an 
oxysulfonium intermediate. Correspondingly, the fluorinated TPE analog was formed 
during heat-induced degradation of modafiendz, CRL-40,940 and CRL-40,941, 
respectively. When a mixture of modafinil (non-fluorinated) and modafiendz 
(fluorinated) were subjected to GC analysis, 4,4'-(2,2-diphenylethane-1,1-
diyl)bis(fluorobenzene) was detected as a third cross reaction product in addition to 
the two expected TPE analogs. These observations served as a reminder that the 
seemingly straightforward implementation of GC-MS analysis can lead to challenges 
during routine analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
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Modafinil (Figure 1) has been used for treating excessive daytime sleepiness or 
narcolepsy without interfering with nocturnal sleep[1,2] and it is well tolerated with little 
or no side effects.[3] It was also reported in a case of doping violation in 2003 at the 
World Track and Field Championship for the first time[4] followed by inclusion in the 
stimulant-drug list prohibited by the World Anti-Doping Agency (WADA) in 2004.[5] 
The pharmacokinetics of modafinil has been well studied and it is primarily 
hydrolyzed by esterases and amidases to modafinic acid, which is its major 
metabolite.[3,6,7] 
Studies have also identified that modafinil might be useful to treat cocaine 
dependence as it was found to reduce cocaine self-administration and cocaine 
reduced euphoria in human studies.[8-10] However, a 2012 randomized study, 
involving cocaine dependent subjects using cocaine (0 mg/day, 200 mg/day or 400 
mg/day), with a once per week cognitive behavioral therapy session, indicated that 
modafinil had no effect.[11]  Investigations have shown[12-13] that modafinil is ineffective 
for the treatment of cocaine dependence in cocaine-depended subjects without 
comorbid alcohol dependence. In separate trials,[14,15] there was evidence that 
cocaine-dependent individuals, without co-morbid alcohol dependence, treated with 
modafinil had showed usefulness as a treatment for these patients.  
Modafinil can be considered an interesting alternative to current amphetamine based 
medications that show high abuse liability and dependence producing properties.  As 
a result of its presumed lower potential for abuse and lack of peripheral 
sympathomimetic effects that are associated with amphetamine stimulants, it has 
also been researched for off-label use to treat sedation associated with other 
disorders such as parkinsonism, fatigue in human immunodeficiency virus (HIV) 
infection, multiple sclerosis, cancer and attention deficit hyperactivity disorder 
(ADHD).[16-20] The mechanism of action of modafinil is complex and poorly 
understood. Studies regarding its effects on dopaminergic pathways and evidence 
regarding effects on serotonergic and GABAergic pathways are reviewed elsewhere. 
[21] The standard therapeutic dose of modafinil in adult patients is 200-400 mg 
daily.[22]   
Although originally prescribed to help narcoleptic patients stay awake and alert there 
are studies reporting improved performance that came alongside its wakefulness 
properties.[23] Due to its off-label use for improved performance, modafinil has been 
sought by healthy individuals to improve user performance in specific tasks[24] In 
addition modafinil use has been noted regarding enhancing task ability versus 
cheating in other fields.[25] Studies showed that neuropsychological performance was 
improved by increasing short-term memory and boosting an individual’s ability to plan 
and process information.[24,26] Use of cognitive enhancers is gaining ground. In 2008, 
the journal Nature presented the results of an informal survey polling readers 
regarding the use of three specific cognition enhancement agents. The results 
showed that 20% of the respondents reported the use of such agents for 
nontherapeutic enhancement purposes. In addition, 69% of the respondents agreed 
that healthy adults should have the choice to use cognitive enhancement agents.[27] 
In 2016, an online survey was carried out to evaluate pharmacological enhancement 
of professional workers in the field of economics. A total of 1021 participants 
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completed the anonymous survey and results showed that lifetime use of any drug 
for neuroenhancement was 88% and for the use of illicit or prescription drugs was 
19%.[28] Poll participants stated reasons such as “curiosity”, “to enhance mood”, “for a 
confident appearance”, “stress/pressure to perform” and “deadline pressure” for use 
of such substances. 
 
Modafinil has rapidly gained a positive reputation for improving attention, executive 
function and memory.[29] The interest in the off-label use of modafinil in the media has 
directed the general public and scientific community towards brain-boosting nootropic 
supplements. Nootropic supplements are substances claimed to improve cognitive 
function, particularly attention, executive function and memory in healthy patients. 
Such supplements are easy to purchase through online vendors. A popular modafinil 
alternative is the N-hydroxy derivatve of modafinil called adrafinil (2-
((diphenylmethyl)sulfinyl-N-hydroxyacetamide) (Figure 1). Adrafinil is also a pro-drug 
and it is metabolized, mainly in the liver, to its bioactive amide, modafinil.[30] CRL-
40,940 (Figure 1) is also advertised as a wakefulness promoting agent that 
represents the bisfluoro analog of modafinil but it has also been reported as a so-
called designer drug.[31-34] CRL-40,941 and modafiendz are also wakefulness 
promoting agents and related to modafinil and adrafinil (Figure 1).  
 
Customs and forensic laboratories are increasingly encountering these substances in 
both tablet and powdered forms. The first detection of modafinil has been reported to 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) via the 
European Union early warning system (EWS) in 2015.[35] Both adrafinil and 
modafiendz detections were first reported in 2014.[36] In Ireland, a recent media 
report (April 2016) indicated that there has been a surge in the purchasing of smart-
drugs illegally on the dark web.[37] The three most popular smart-drugs detected 
smuggled into Ireland were amphetamine, dextroamphetamine, methylphenidate and 
modafinil.  
Gas chromatography mass spectrometry (GC-MS) s widely utilized in forensic 
chemistry laboratories and is regarded as a robust methodology but, in the case of 
thermally labile compounds, analytical challenges arise when attempting to 
investigate the analytical profile. This study reports on the thermal degradation of 
modafinil, adrafinil, modafinic acid, CRL-40,940 and CRL-40,941 in the GC injector 
and the formation of  common degradation products, i.e. 1,1,2,2-tetraphenylethane, 
and its fluoro analog. This study confirmed the presence of the degradants by 
comparison with authenticated synthesized standards. As the popularity and 
abundance of neuroenhancement drugs appears to be increasing, it is expected that 
challenges faced by customs and forensic laboratories might arise when employing 
GC-MS as the standard tool of analysis, similar to what has been reported for other 
drugs.[38] 
 
Experimental 
 
All reagents and dry solvents used in the syntheses were obtained from Sigma 
Aldrich Ltd (Arklow, Co. Wicklow, Ireland). LC-MS grade solvents were obtained from 
Fisher Scientific (Dublin, Ireland).  
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1,1,2,2-Tetraphenylethane 
 
A solution of 1,1,2,2-tetraphenylethylene (250 mg, 0.75 mmol) in ethyl acetate (40 
mL), containing palladium on charcoal (10%, 150 mg) was stirred under an 
atmosphere of hydrogen for 96 h. The catalyst was removed by filtration and the 
solvent was then removed to afford a colorless solid (161 mg, 0.50 mmol, 67%): 
m.pt. 198-200 oC (recrystallized from ethyl acetate/acetonitrile); 1H NMR (CDCl3) δ 
7.18-7.23 (m; 8 H; Ar-H), 7.11-7.17 (m; 8 H; Ar-H), 7.03-7.08 (m; 4H; Ar-H) and 4.81 
(s; 2H, CH) ppm; 13C NMR (CDCl3) δ 143.46 (Ar-C), 128.52 (Ar-CH), 128.15 (Ar-CH), 
125.86 (Ar-CH) and 56.33 (CH) ppm. The compound did not produce a suitable 
quasimolecular ion for accurate mass determination. 
 
2-(Benzhydrylsulfinyl)acetic acid (modafinic acid) 
 
Aqueous hydrogen peroxide solution (35 % wt., 0.43 mL, 5.0 mmol) was added to a 
solution of 2-(benzhydrylthio)acetic acid (1.28 g, 5 mmol) in glacial acetic acid (8 mL) 
and the mixture was allowed to stand at room temperature for 2 h. The solvent was 
allowed to evaporate overnight and the residue was recrystallized from acetonitrile to 
afford colorless crystals (814 mg, 3.0 mmol, 60%): m.pt. 144-146 oC; 1H NMR (d6 
DMSO) δ 13.23 (s; 1H; OH), 7.52-7.56 (m; 4H; Ar-H), 7.33-7.47 (m; 6H; Ar-H), 5.43 
(s; 1H; CH), 3.58 (d; J = 14.3 Hz; 1H, one H from CH2) and 3.35 (d; J = 14.3 Hz; 1H, 
one H from CH2) ppm; 
13C NMR (d6 DMSO) δ 167.84 (C=O), 137.07 (Ar-C), 135.34 
(Ar-C), 130.06 (Ar-CH), 129.58 (Ar-CH), 129.04 (Ar-CH), 128.96 (Ar-CH), 128.57 (Ar-
CH), 128.51 (Ar-CH), 69.69 (CH) and 55.88 (CH2) ppm: ESI HRMS: Found m/z 
273.0569 (calc. for [M-H]-,C15H13O3S, m/z 273.0580, Δ  = -4.03 ppm). 
 
Modafinil 
 
Purchased from Sigma Aldrich (EPCRS grade): m.pt. 164-166 oC 1H NMR (d6 
DMSO) δ 7.70 (s; 1H; one H from NH2), 7.50-7.56 (m; 4H; Ar-H), 7.31-7.45 (m; 7H; 
Ar-H and one H from NH2), 5.36 (s; 1H; CH), 3.38 (d; J = 13.6 Hz; 1H, one H from 
CH2) and 3.23 (d; J = 13.6 Hz; 1H, one H from CH2) ppm; 
13C NMR (d6 DMSO) δ 
166.35 (C=O), 137.20 (Ar-C), 134.92 (Ar-C), 129.70 (Ar-CH), 129.03 (Ar-CH), 128.48 
(2 x Ar-CH), 127.95 (Ar-CH), 127.92 (Ar-CH), 68.71 (CH) and 56.15 (CH2) ppm; ESI 
HRMS: Found m/z 296.0706 (calc. for [M+Na]+, C15H15NO2NaS, m/z 296.0716, Δ  = 
-3.37 ppm). 
 
 
 
 
Adrafinil 
 
Purchased from Scientific Supplies Ltd (London, UK) in 2015 and recrystallized from 
acetonitrile/ethanol to afford almost colorless crystals: m.pt. 140-142 oC; 1H NMR (d6 
DMSO) δ 10.81 (s; 1H; NOH), 9.17 (s; 1H; NH), 7.51-7.57 (m; 4H; Ar-H), 7.31-7.48 
(m; 6H; Ar-H), 5.41 (s; 1H; CH), 3.35 (d; J = 13.4 Hz; 1H, one H from CH2) and 3.08 
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(d; J = 13.4 Hz; 1H, one H from CH2) ppm; 
13C NMR (d6-DMSO) δ 161.14 (C=O), 
137.01 (Ar-C), 134.85 (Ar-C), 129.68 (Ar-CH), 129.07 (Ar-CH), 128.53 (Ar-CH), 
128.51 (Ar-CH), 128.02 (Ar-CH), 127.97 (Ar-CH), 68.93 (CH) and 43.83 (CH2) ppm; 
ESI HRMS: Found m/z 312.0653 (calc. for [M+Na]+, C15H15NO3NaS, m/z  312.0665, 
Δ  = -3.84 ppm). 
 
2-(Benzhydrylthio)acetamide 
 
A mixture of 2-(benzhydrylthio)acetic acid (1.034 g, 4 mmol), thionyl chloride (595 
mg, 5 mmol) and toluene (10 mL) was refluxed for 1 hr. The mixture was allowed to 
cool to room temperature and the volatiles were removed under vacuum. The 
residue was dissolved in dichloromethane (20 mL) and a solution of methanolic 
ammonia (7 M, 4 mL) in dichloromethane (40 mL) was added slowly. The mixture 
was stirred at room temperature for 30 minutes and then centrifuged (3,000 rpm for 5 
min.). The supernatant was collected, evaporated to dryness to afford a colorless 
solid (941 mg). A portion (533 mg) was purified by preparative TLC (silica gel, 2 mm; 
ethyl acetate/hexane, 8/2) to afford a colorless solid (253 mg, 35 %): m.pt. 108-110 
oC; 1H NMR (d6 DMSO) 7.47-7.40 (m; Ar-H and one NH; 5H), 7.37-7.31 (m; 4H; Ar-
H), 7.27-7.22 (m; 2H; Ar-H), 7.03 (s; 1H; NH), 5.41 (s; 1H; CH) and 2.95 (s; 2H; CH2); 
13C NMR (d6 DMSO) δ 170. 81 (C=O), 141.70 (Ar-C), 129.03 (Ar-CH), 128.47 (Ar-
CH), 127.62 (Ar-CH), 53.42 (CH) and 35.38 (CH2); ESI HRMS Found: m/z  280.0773 
(calc. for [M+Na]+, C15H15NOSNa, m/z  280.0772, Δ  = 0.4 ppm).  
 
2-((Bis(4-fluorophenyl)methyl)sulfinyl)-N-methylacetamide (Modafiendz)  
 
Purchased from Scientific Supplies Ltd (London, UK). M.pt. 86-88 oC; 1H NMR (d6-
DMSO) δ 8.17 (q; J = 4.6 Hz, 1H; NH), 7.50-7.59 (m; 4H; Ar-H), 7.23-7.30 (m;  4H; 
Ar-H), 5.43 (s; 1 H; CH), 3.44 (d; J = 13.4 Hz; 1H; 1 H from CH2), 3.17 (d; J = 13.4 
Hz; 1H; 1H from CH2) and 2.57 (d, J = 4.6 Hz; 3H; CH3); 
13C NMR (d6 DMSO) δ 
164.44 (C=O), 161.91 (d; JC,F  = 245 Hz; Ar-C), 161.64 (d; JC,F  = 245 Hz; Ar-C), 
133.24 (d; JC,F  = 3 Hz; Ar-C), 131.65 (d; JC,F  = 8 Hz; Ar-CH), 130.73 (d; JC,F  = 3 Hz; 
Ar-C), 130.56 (d; JC,F  = 8 Hz; Ar-CH), 115.86 (d; JC,F  = 21 Hz; Ar-CH), 115.34 (d; JC,F  
= 21 Hz; Ar-CH), 66.53 (CH), 56.22 (CH2) and 25.70 (CH3); ESI HRMS: Found m/z  
324.0869 (calc. for [M+H]+, C16H16F2NO2S, m/z  324.0864, Δ  = 1.54 ppm). 
 
2-((Bis(4-fluorophenyl)methyl)sulfinyl)acetamide (CRL-40,940)  
Purchased from NewMind (Chicago, USA). M.pt. 130-132 oC; 1H NMR (d6 DMSO) δ 
7.68 (s; 2H; NH), 7.50-7.61 (m; 4H; Ar-H), 7.33 (s; 1H, NH), 7.22-7.31 (m; 4H; Ar-H), 
5.41 (s; 1H; CH), 3.41 (d; J = 13.7 Hz; 1H; 1H from CH2) and 3.17 (d; J = 13.7 Hz; 
1H; 1H from CH2); 
13C NMR (d6 DMSO) δ 166.17 (C=O), 161.89 (d; JC,F  = 245 Hz; 
Ar-C), 161.63 (d; JC,F  = 245 Hz; Ar-C), 133.35 (d; JC,F  = 3 Hz; Ar-C), 131.65 (d; JC,F  = 
8 Hz; Ar-CH), 130.75 (d; JC,F  = 3 Hz; Ar-C), 130.51 (d; JC,F  = 8 Hz; Ar-CH), 115.86 (d; 
JC,F  = 21 Hz; Ar-CH), 115.32 (d; JC,F  = 21 Hz; Ar-CH), 66.37 (CH) and 56.17 (CH2); 
19F NMR (d6 DMSO) -114.04 and -114.18 ppm; ESI HRMS Found 332.0533 (calc. for 
[M+H]+, C15H13F2NO2SNa, 332.0533, Δ = 0.0 ppm). 
 
2-((Bis(4-fluorophenyl)methyl)sulfinyl)-N-hydroxyacetamide (CRL- 40,941)  
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Purchased from NewMind (Chicago, USA). M.pt. 110-112 oC; 1H NMR (d6 DMSO) δ 
10.78 (s; 1 H, OH), 9.17 (s; 1H; NH), 7.50 – 7.63 (m; 4H; Ar-H), 7.21-7.32 (m; 4H; Ar-
H), 5.46 (s; 1H; CH), 3.39 (d; J = 13.3 Hz; 1H; 1H from CH2) and 3.02 (d; J = 13.3 
Hz; 1H; 1H from CH2); 
13C NMR (d6 DMSO) δ 160.99 (C=O), 161.95 (d; JC,F  = 245 
Hz; Ar-C), 161.69 (d; JC,F  = 245 Hz; Ar-C), 133.16 (d; JC,F  = 3 Hz; Ar-C), 131.67 (d; 
JC,F  = 8 Hz; Ar-CH), 130.66 (d; JC,F  = 3 Hz; Ar-C), 130.57 (d; JC,F  = 8 Hz; Ar-CH), 
115.93 (d; JC,F  = 21 Hz; Ar-CH), 115.39 (d; JC,F  = 21 Hz; Ar-CH), 66.64 (CH) and 
53.83 (CH2); 
19F NMR (d6 DMSO) -113.90 and -114.08 ppm; ESI HRMS: Found m/z 
324.0491 (calc. for [M-H]-, C15H12F2NO3S, m/z  324.0506,Δ  = -4.6 ppm). 
 
1,1,2,2-Tetrakis(4-fluorophenyl)ethane 
 
A mixture of 4,4’-difluorobenzophenone (2.18 g, 10 mmol), thionyl chloride (1.81 mL, 
25 mmol) and DMF (0.75 mL) was heated at 75 °C for 20 h. After cooling to room 
temperature, the reaction mixture was poured into ice-cold water (with thorough 
mixing) and extracted with toluene. The organic extract was dried (anhydrous 
magnesium sulfate) and the volatiles were removed under vacuum to afford a 
colorless oil (2.34 g, 8.8 mmol). Toluene (10 mL) and copper-tin alloy (2.0 g) were 
added and the mixture was refluxed for 3 h. After cooling to room temperature, the 
mixture was washed with aqueous hydrochloric acid (2 M), centrifuged (3,000 rpm for 
5 min) and the organic layer was collected. Removal of the volatiles under vacuum 
afforded a light brown semi-solid (1.70 g). A portion of this (600 mg) was purified by 
preparative TLC (silica gel, 2 mm; hexane) to afford a colorless powder (124 mg). 
This was dissolved in ethyl acetate (10 mL), palladium on charcoal (10 %, 200 mg) 
was then added and the mixture was stirred under an atmosphere of hydrogen for 48 
h. Analysis by GC-MS revealed about 40% conversion (peak areas). More ethyl 
acetate (10 mL) and palladium on charcoal (10%, 200 mg) were then added and 
hydrogen was bubbled through the mixture for 30 min. The mixture was then stirred 
under an atmosphere of hydrogen for 24 h. The catalyst was removed by filtration 
and the filtrate was evaporated to dryness to afford an almost colorless solid. This 
was recrystallized (ethyl acetate/hexane) to give colorless crystals (29 mg, 4%): m.pt. 
258-262 oC; 1H NMR (CDCl3) δ 7.03-7.10 (m; 8H; Ar-H), 6.81-6.90 (m; 8H; Ar-H) and 
4.65 (s; 2H; CH); 13C NMR (CDCl3) δ 161.14 (d; JC,F  = 245 Hz; Ar-C), 138.56 (d; JC,F  
= 3 Hz; Ar-C), 129.70 (d; JC,F  = 8 Hz; Ar-CH), 115.23 (d; JC,F  = 21 Hz; Ar-CH), 115.39 
(d; JC,F  = 21 Hz; Ar-CH) and 55.11 (CH); 
19F NMR (d6 DMSO) δ -116.51 ppm. The 
compound did not produce a suitable quasimolecular ion for accurate mass 
determination. 
 
Instrumentation 
 
Gas chromatography-mass spectrometry (GC-MS) 
 
Samples were analyzed on an Agilent 6890N gas chromatograph coupled to a 5975 
insert MSD. A HP ULTRA 1 column (12 m × 0.2 mm × 0.33 µm) was used in split 
mode (1:1 or as stated) with helium carrier gas at a constant flow of 0.8 mL/min. The 
injection port and transfer line temperatures were set at 250°C and 280°C 
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respectively. The initial oven temperature was 60°C, held for 2 minutes and then 
ramped at 25 °C/min to 295 °C with a final hold time of 3 min (run time 14.4 min). 
The ionization energy was set at 70 eV, the quadrupole at 150°C, the ion source at 
230 °C and the mass range was m/z 40-550. 
 
Gas chromatography ion trap mass spectrometry 
 
Electron ionization mass spectra were recorded under standard conditions. Chemical 
ionization mass spectra were recorded using HPLC grade methanol as the liquid CI 
reagent. A Varian 450-GC gas chromatograph coupled to a Varian 220-MS ion trap 
mass spectrometer and a Varian 8400 autosampler was employed with a Varian CP-
1177 injector (275 ºC) in split mode (1:50) (Walnut Creek, CA, USA). The Varian MS 
Data Review function of the Workstation software, version 6.91, was used for data 
acquisition. The carrier gas was helium at a flow rate of 1 mL/min using the EFC 
constant flow mode. The default settings for CI ionization parameters (0.4 s/scan) 
were used: CI storage level m/z 19.0; ejection amplitude m/z 15.0; background mass 
m/z 55; maximum ionization time 2000 µs; maximum reaction time 40 ms; target TIC 
5000 counts. Temperatures for ion trap, manifold, and transfer line were set at 170 
°C, 120 °C, and 280 °C, respectively. An Agilent J&W VF-5ms GC column (30 m × 
0.25 mm, 0.25 µm) was employed for separation. The starting temperature was set 
at 80 ºC and held for 1 min. Th  temperature then increased at 20 ºC/min to 280 ºC 
and held constant for 9 min to give a total run time of 20.00 min. 
 
High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) 
 
Instrument 1: HR-ESI mass spectra were recorded by direct injection into a LTQ 
Orbitrap Discovery (Thermo Fisher Scientific, Bremen, Germany). Samples were 
dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) and infused at a rate 
of 5 µL/min. Full accurate high-resolution (30 000) mass scans were performed in 
positive electrospray mode. Measured accurate masses were within ± 5 ppm of the 
theoretical masses. The following conditions were used: drying gas (N2) 10 L/min, 
capillary temperature 310 °C, spray voltage 4 V, capillary voltage 22 V and tube lens 
77 V. Mass calibrations were performed in both positive and negative mode using 
solutions of caffeine, L-methionyl-arginyl-phenylalanylalanine acetate × H20 (MRFA), 
Ultramark 1621®, sodium docecyl sulfate and sodium taurocholate. 
 
Instrument 2: ESI mass spectra were also acquired using a Micromass LCT Classic 
ToF mass spectrometer interfaced to a Waters 2690 HPLC. Leucine Enkephalin was 
used as an internal lock mass. Operating conditions were as follows: ESI capillary 
voltage 2500 V, cone voltage 25 V, desolvation temperature 300°C, source 
temperature 100°C. MassLynx™ 4.0 software was used to carry out the analysis.     
 
Liquid chromatography-mass spectrometry (LC-MS) 
 
LC-MS analyses were performed on an Agilent 1100 HPLC system equipped with a 
G13795 degasser, G1312A BinPump, a G1313A ALS and G1316A column oven 
(COLCOM) (Agilent, Little Island, Cork, Ireland). Separation was obtained on a 
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Kinetex phenyl-hexyl column (2.6 µm, 100 x 2.10 mm) Phenomenex (Macclesfield, 
Cheshire, United Kingdom). The analytes were eluted under isocratic conditions 
using a mobile phase of 97% water and 3% acetonitrile (both containing 0.1% formic 
acid). The Agilent single quadrupole MSD settings were as follows: positive 
electrospray mode, capillary voltage 3500 V, drying gas (N2) 12 L/min at 350 °C, and 
nebulizer gas (N2) pressure 50 psi. In-source collision-induced dissociation 
experiments were carried out with an increased fragmentor voltage of 110 V. 
Samples were dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) at a 
concentration of 10 µg/mL. The injection volume was 0.5 µL, flow rate was 0.4 
mL/min and the column temperature was set at 30 °C. Total run time was 25 min. 
 
Nuclear magnetic resonance spectroscopy (NMR) 
 
All samples were prepared in the stated deuterated solvent at a concentration of 20 
mg/mL. 1H (600 MHz) and 13C (150 MHz, referenced to the NMR solvent peak) 
spectra were recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI 
cryoprobe. 1H NMR spectra were referenced to an external TMS reference at δ = 0 
ppm. 19F (376 MHz) spectra were recorded on a Bruker DPX400 NMR spectrometer 
and the external reference was trifluorotoluene set at δ = -64 ppm. 
 
X-Ray crystallography for 1,1,2,2-tetraphenylethane 
Data was collected on a Bruker D8 Quest ECO with Mo Kα radiation (λ = 0.71073 
Å) using a MiTeGen micromount and at 100(2) K (Oxford Cryosystem). Bruker 
APEX3[39] software was used to collect and reduce data, determine the space group, 
solve and refine the structure. Absorption corrections were applied using SADABS.[40] 
All final refinements were performed with OLEX/SHELXL.[41,42] The molecule exhibits 
complete molecular disorder with each moiety at 50% occupancy, except for H7 and 
H7a which are shared at 100% occupancy between each disordered moiety. H7 and 
H7a were located and refined. All non-hydrogen atoms were refined anisotropically 
using constraints (EADP). Hydrogen atoms (with the exception of H7, H7a) were 
assigned to calculated positions using a riding model. See below for crystal data and 
structure refinement parameters. CCDC 1483400 contains the supplementary 
crystallographic data (see Supporting Information 1): C26H22, M = 334.43, T = 100(2) 
K, Monoclinic, C2/c, a = 17.5758(9), 5.8709(3), c = 17.5462(10) Å, β= 91.110(3)°, V 
= 1810.18(17) Å3, Z = 4, µ (Mo Kα) = 0.069 mm−1, ρ = 1.227 Mg/cm3, 14094 
reflections collected, 1915 independent (Rint = 0.0857), 
aR1 = 0.0566, wR2 = 0.1063 (I 
> 2σ(I)), S = 1.032. CCDC 1483400 aR1 = Σ||Fo| − |Fc||/Σ|Fo|, wR2 = [Σw(Fo2 − 
Fc
2)2/Σw(Fo2)2]1/2. 
 
Results and discussion 
 
Previously, a GC-MS method was reported for the detection of modafinil in human 
urine. [43] The authors extracted modafinil from drug-spiked urine samples and 
analyzed directly by GC-MS. Two other characteristic ions, related to the 
diphenylmethyl fragment (m/z 167), namely m/z 165 and m/z 152, were identified in 
the mass spectrum. It was stated that the reason for obtaining the single artifact peak 
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merited further investigation although it was not identified. It has been reported that 
modafinil, adrafinil and modafinic acid are significantly degraded under EI-GC-MS 
conditions,[44] therefore resulting in an artifact peak for modafinil, adrafinil and 
modafinic acid that eluted as a single peak at the same retention time. In that study, 
the artifact peak was used as a marker for screening purposes. A possible site of 
ionization in the modafinil structure is the diphenylmethyl sulfinyl linkage and, as 
expected, the main fragment derives from this at m/z of 167 (base peak). 
Subsequently, demethylation occurs, yielding m/z 152 as the second major fragment. 
The authors showed that the operation of the GC at high temperature gave rise to 
the single artifact peak at the same retention time in each chromatogram albeit the 
authors did not identify this compound.[44] Other authors have reported modafinil as 
being thermally labile and unsuitable for GC-MS analysis.[44-46]  
In the work presented in this study, modafinil, adrafinil and modafinic acid were found 
to produce similar GC chromatograms when acetonitrile, dichloromethane or ethanol 
were used as solvents (Figure 2a, Supporting Information 2). Two major peaks were 
present and identified as diphenylmethanol (6.75 min) and 1,1,2,2-tetraphenylethane 
(10.22 min). However, diphenylmethane (5.81 min) and thiobenzophenone (7.05 min, 
Supplemental 2) were also identified in some instances. Possible mechanisms for 
the formation of diphenylmethane and diphenylmethanol are presented in Figure 2a 
and the EI mass spectrum of 1,1,2,2-tetraphenylethane is shown in Figure 2b (with a 
magnification in Figure 2c). It displays a very weak molecular ion, m/z 334, and a 
number of fragments that potentially arise from ion/hydrogen scrambling. It has 
previously been reported that the benzhydrylium ion, m/z 167, which is in rapid 
equilibration with the phenyl tropylium ion, transitions to m/z 152 by loss of a methyl 
radical, formed from the bridging CH unit and two ortho hydrogens.[47-50] As the 
formation of ions, such as m/z 239 and m/z 252, are not readily rationalized, it is 
suggested that these might also arise from ion scrambling mechanisms. 
Conventionally, dimerization of two diphenylmethyl radicals (Ph2CH), formed by the 
thermolysis of modafinil or a related compound, may lead to the formation of 1,1,2,2-
tetraphenylethane.[51,52] However, an alternative mechanism (Figure 3) involves the 
initial formation of the well-known and characterized benzhydrylium 
(diphenylcarbonium) ion.[53-55] It is suggested that thermal degradation of modafinil, 
adrafinil or modafinic acid could result in the formation of a benzhydrylium ion (Figure 
3a). The benzhydrylium ion may then form an oxysulfonium intermediate with the 
sulfoxide oxygen on modafinil, adrafinil or modafinic acid. This oxysulfonium salt may 
then degrade to 1,1,2,2-tetraphenylethane via a benzhydryl oxy sulfide species 
(Figure 3b). Interestingly, the analogous dibenzhydryl disulfide has been shown to 
decompose on heating to yield 1,1,2,2,-tetraphenylethane[56,57] and oxysulfonium 
salts have also been reported previously.[58-60] When equimolar (30-970 µM) 
acetonitrile solutions of modafinil or modafinil sulfide (Figure 3c) were injected 
separately on to the GC, the relative amount of 1,1,2,2-tetraphenylethane formed, 
based upon peak areas, was on average approximately 90 % lower for the sulfide 
(Supporting Information 3), indicating the sulfoxide oxygen may promote thermal 
degradation by the facile formation of the oxysulfonium intermediate. The sulfur lone 
pairs in modafinil sulfide may less readily form a sulfonium salt intermediate with the 
benzhydrylium ion (Figure 3c), thus resulting in relatively lower yields of 1,1,2,2-
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tetraphenylethane. It may be also the case that the postulated intermediate, 
dibenzhydryl sufide, is more thermally stable than the corresponding oxysulfide. 
Varying the split ratio in the GC injector was evaluated but degradant formation was 
still observed (Supporting Information 4).  
 
Interestingly, in the electrospray ionization mass spectra of modafinil and adrafinil, 
oxysulfonium (M + benzhydrylium ion)+ adducts were observed (Supporting 
Information 5), which were consistent with triphenylcyclopropenylium cations that 
undergo adduct formation in the presence of nucleophiles such as thiols.[61] 
 
CRL-40,490 is the fluoro analog of modafinil, CRL-40,491 is the fluoro analog of 
adrafinil and modafiendz (for analytical data see Supporting Information 6) is the N-
methyl analog of modafinil, respectively. The corresponding fluoro-analogs of 
modafinil and adrafinil, namely CRL-40,490 and CRL-40,491, yielded analogous 
fluorinated degradants indicating that a similar mechanism was implicated. When a 
mixture of a non-fluorinated and fluorinated derivatives was injected, a mixture of 
three tetraphenylethanes are observed that represented one hetero and two homo 
coupling products. For example, this was observed when a mixture of modafinil and 
modafiendz (Figure 1) was subjected to GC analysis. The formation of a cross-
reaction product was detected at 11.76 min (Figure 4a) along with the two expected 
diphenylmethane dimers. The cross-reaction product represented the fact that 
modafinil did not contain the two fluorine atoms attached to modafiendz. 
The CI mass spectra for the three tetraphenylethane products are shown in Figure 
4b. In each case, it was not possible to obtain the protonated molecule due to loss of 
either benzene or fluorobenzene from the molecule. With 1,1,2,2-tetrakis(4-
fluorophenyl)ethane (the modafiendz degradation product), CI did not provide any 
more information other than m/z 311 obtained by loss of fluorobenzene, and for 4,4'-
(2,2-diphenylethane-1,1-diyl)bis(fluorobenzene) (the modafinil-modafiendz cross-
reaction product), m/z 293 was obtained following loss of benzene and m/z 275 was 
obtained by loss of benzene, respectively. With the modafinil product (1,1,2,2-
tetraphenylethane), the protonated ion also lost benzene from m/z 257. The 
formation of diphenylmethanol and its fluoro analog (bis(4-fluorophenyl)methane) 
was also observed (Supporting Information 7). Interestingly, both 1,1,2,2-
tetraphenylethane and 1,1,2,2-tetrakis(4-fluorophenyl)ethane also failed to produce 
molecular ions using atmospheric-pressure chemical ionization. This further 
highlighted the complexities expected when customs/forensic seized samples 
contain mixtures of these compounds. 
Both 1,1,2,2-tetraphenylmethane and 1,1,2,2-tetrakis(4-fluorophenyl)ethane were 
synthesized, and characterized. X-ray crystallographic analysis of 1,1,2,2-
tetraphenylmethane was also performed. Clear colorless plates were isolated from a 
hexane solution and the structure determined at 100K. The data were solved and 
refined in the monoclinic space group C2/c. The asymmetric unit consists of one half 
occupied molecule and symmetry generates the complete disordered molecule 
(symmetry operation = 1-x, y, 1.5-z, Figures 5a and 5b). Hydrogen atoms H7 and 
H7a, which are fully occupied, are shared between each disordered molecule. These 
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hydrogen atoms lie on the two-fold rotation axis. The molecule is in the anti-
conformation with a C7-C7a bond length of 1.548(5) Å and C7-ring of 1.530(6) and 
1.507(6)Å. The torsion angles between the ring/ethane/ring carbons are ca. -173.6(4) 
and -173.4(4)° (C6-C7-C7a-C6a and C8-C7-C7a-C8a respectively). The dihedral 
angles between the substituents in the Newman projection are given in Figure 5c 
where 60° is the ideal. The anti-conformation dihedral is ca. 5-6° off the ideal of 180°. 
The structure has been reported previously and is similar to that shown here. In the 
literature model, reported at room temperature in the Space Group A2/a with 
comprehensive disorder modeling, the ethane C-C distance is recorded as 1.540 and 
1.556Å for each disordered moiety.[62] In this structure, the ring atoms were not 
completely modeled as disordered. Overall, the x-ray structure data were fully 
consistent with the structure.   
Analysis of CRL-40,940 (flmodafinil) and CRL-40,941 (fladrafinil) (LCMS data for 
both compounds shown in Supporting Information 8) by GC-MS revealed the 
formation 1,1,2,2-tetrakis(4-fluorophenyl)ethane (Supporting Information 9), in a 
similar manner to modafiendz. The para-fluoro analogs of diphenylmethane, 
benzophenone and diphenylmethanol (major product) were also observed in both 
cases. Interestingly, CRL-40,9401 also produced a small amount of the 
thiobenzophenone derivative but it was not possible to distinguish between the two 
compounds. These observations might have significant implications for forensic drug 
analysis given that CRL-40,940, CRL-40,941 and modafiendz produced similar 
degradant profiles. The GC-MS method used in this study is typical of routine 
forensic screening protocols. Essentially our group replicated conditions using 
methodologies widely utilised in most laboratories on a routine basis and therefore 
other laboratories might encounter similar issues regarding degradation for these 
compounds. 
 
 
Conclusion 
 
The nootropics phenomenon is an area of investigation that attracts attention from 
multi-disciplinary stakeholders who face the challenge of keeping up-to-date with 
older substances used in newly emerging off-label ways where few data are 
available that aid their identification. This study identified a common GC injector port 
thermolysis product in the analysis of modafinil, adrafinil and modafinic acid and a 
mechanism for its formation was proposed. Caution should be exercised in the 
analysis of modafinil and adrafinil and potentially other nootropic agents containing a 
similar molecular skeleton. CRL-40,940, CRL-40,941 and modafiendz produced the 
same degradant profile which could lead to ambiguity during forensic analysis. The 
characterization of modafinil, adrafinil, modafinic acid, CRL-40,940, CRL-40,941 and 
modafiendz yielded a set of analytical data that were collected to serve research 
communities involved with the study of these substances in both customs/forensic 
laboratories and clinical applications. The monitoring of these compounds is 
important and analytical data presented in this study allows the scientific community 
to support this endeavor.  
GC-MS is frequently implemented in a customs or forensic laboratory setting due to 
its high sensitivity, fast analysis time, low cost, excellent separation and identification 
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capabilities. However, special attention should be paid to the potential for ambiguity 
when using this technique. 
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Figure captions 
Figure 1. Molecular structures of compounds discussed in manuscript 
Figure 2.  (a). Typical GC chromatogram for modafinil, adrafinil or modafinic acid 
(chromatogram for modafinil shown) along with mechanisms for the formation of 
dipheylmethane and dipheylmethanol, (b). EI mass spectrum and potential fragments 
for 1,1,2,2-tetraphenylethane and (c). magnification of 1,1,2,2-tetraphenylethane 
mass spectrum. 
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Figure 3.  Potential mechanism for the formation of 1,1,2,2-tetraphenylethane: (a) 
formation of the benzhydrium ion, (b). reaction of modafinil with the benzhydrylium 
ion to form 1,1,2,2-tetrapheylethane and (c). formation of 1,1,2,2-tetrapheylethane 
from modafinil sulfide. 
 
Figure 4. (a). Chromatograms depicting the formation of 1,1,2,2-tetrapheylethane, its 
di-fluoro and tetra-fluoro analogs, following the injection of modafinil, modafiendz or 
co-injection of modafinil and modafiendz and (b). ion trap CI and EI mass spectra for 
1,2,2-tetraphenylethane, its di-fluoro and tetra-fluoro analogs 
 
Figure 5. (a). Structure 1,1,2,2-tetraphenylethane showing one symmetry unique 
complete conformation at 50% occupancy (excluding H7, H7a). Atomic displacement 
shown at 50% probability, (b). Partially labelled symmetry generated (1-x, y, 1.5-z) 
complete molecule of 1. One disordered molecule is labeled completely and only H7 
and H7a shown for clarity and (c). Newman projection down the C7-C7a ethane axis 
showing the anti-conformation of the molecule with the dihedral angles shown. 
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Figure 2.  (a). Typical GC chromatogram for modafinil, adrafinil or modafinic acid (chromatogram for 
modafinil shown) along with mechanisms for the formation of dipheylmethane and dipheylmethanol, (b). EI 
mass spectrum and potential fragments for 1,1,2,2-tetraphenylethane and (c). magnification of 1,1,2,2-
tetraphenylethane mass spectrum.  
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Figure 4. (a). Chromatograms depicting the formation of 1,1,2,2-tetrapheylethane, its di-fluoro and tetra-
fluoro analogs, following the injection of modafinil, modafiendz or co-injection of modafinil and modafiendz  
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Figure 4.  (b). Ion trap CI and EI mass spectra for 1,2,2-tetraphenylethane, its di-fluoro and tetra-fluoro 
analogs  
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